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ABSTRACT
Resistance among Gram-positive organisms has
been steadily increasing over the last several
years; however, the development of new
antibiotics to treat infections caused from
these organisms has fallen short of the
emergent need. Specifically, resistance among
Staphylococcus aureus and Enterococcus spp. to
essential antibiotics is considered a major
problem. Oritavancin is a semisynthetic
lipoglycopeptide antibiotic that was recently
approved for the treatment of acute bacterial
skin and skin structure infections (ABSSSI).
While structurally related to vancomycin,
oritavancin also possesses unique mechanisms
of action that greatly enhance its antimicrobial
potency against multi-drug resistant pathogens
including both VanA- and VanB-mediated
vancomycin-resistant enterococci. Owing to
the addition of the highly hydrophobic tail
group, oritavancin possesses a prolonged
half-life ranging from 200–300 h. Although
oritavancin is only currently Food and Drug
Administration approved for ABSSSI, this agent
may eventually play a role in additional
indications where new innovative therapy is
needed including bacteremia and deep-seeded,
Gram-positive infections such as infective
endocarditis or osteomyelitis. This review will
focus on oritavancin’s spectrum of activity,
mechanisms of action and resistance,
pharmacokinetic and pharmacodynamic
properties, and the completed and ongoing
clinical studies evaluating its use.
Keywords: Acute bacterial skin and skin
structure infection; Lipoglycopeptide;
Oritavancin
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INTRODUCTION
Resistance among Gram-positive organisms has
been steadily increasing over the last several
years; however, the development of new
antibiotics to treat infections caused from
these organisms has fallen short of the
emergent need. Specifically, resistance among
Staphylococcus aureus and Enterococcus spp. to
essential antibiotics in the US is considered a
major problem with 56.8% of S. aureus being
methicillin-resistant (MRSA) and 87.1% of
Enterococcus faecium being vancomycin
resistant (VRE) [1]. Additionally, data from the
most recent US National Healthcare Safety
Network and Center for Disease Control and
Prevention’s report identified these two
organisms as being the most commonly
reported organisms isolated from
hospital-acquired infections [2]. With the high
frequency of these organisms implicated in
serious infections and the concerns with their
resistance to the mainstay of treatment, there is
clearly a need for alternative therapies.
Fortunately, the Food and Drug
Administration (FDA) has recently approved
several new antibiotics for the treatment of
these resistant Gram-positive infections.
Oritavancin is a semisynthetic
lipoglycopeptide antibiotic that is one of the
new agents that was recently approved for the
treatment of acute Gram-positive skin and skin
structure infections. This review will focus on
oritavancin’s spectrum of activity, mechanisms
of action and resistance, pharmacokinetic and
pharmacodynamic properties, and the
completed and ongoing clinical studies
evaluating its use. The search for articles in
this review was performed using the search
terms oritavancin and LY33328 with the
PubMed database for articles published
between the dates of 2010 to 2015.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
CHEMICAL STRUCTURE
Oritavancin is a lipoglycopeptide derived from
the naturally occurring chloroeremomycin, a
member of the eremomycin class of
glycopeptides [3]. While structurally similar to
vancomycin (Fig. 1), the
eremomycin-glycopeptides possess two
4-epi-vancosamine monosaccharides, one
replacing vancosamine and the other linked to
ring-6 via an amino acid residue. Oritavancin
additionally includes a highly hydrophobic
N-alkyl-p-chlorophenylbenzyl substituent
linked to the disaccharide sugar. These
pharmacophore features, as well as associated
modifications in stereochemistry, are believed
to be largely responsible for the greatly
enhanced antimicrobial potency of oritavancin
against Gram-positive organisms including




The progenitors of the lipoglycopeptide class,
the glycopeptides, are known to inhibit
bacterial growth by binding to the
D-alanyl-D-alanine terminus of the
peptidoglycan precursor linked to the C55-lipid
transporter (collectively referred to as Lipid II;
Fig. 2). Lipid II is responsible for transporting
peptidoglycan precursor monomers across the
lipid bilayer and aligning with a template
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peptidoglycan chain to position the monomer
for incorporation to the growing nascent
peptidoglycan chain. When glycopeptides,
such as vancomycin, bind to the terminal
peptide stem of Lipid II, they effectively block
the bacterial enzyme transglycosylase from
transferring the peptidoglycan precursor to the
growing nascent peptidoglycan chain [5]. Thus,
peptidoglycan polymerization is impeded and
cell wall integrity and cell survival are
compromised.
Vancomycin-resistant enterococci (VRE) and
vancomycin-resistant S. aureus (VRSA) elude the
antimicrobial activity of most glycopeptides by
substituting the terminal D-alanine of the
peptidoglycan precursor with D-lactate or
D-serine upon exposure to glycopeptides via a
two-component signaling system [6]. This
substitution greatly decreases the binding
affinity of glycopeptides, such as vancomycin,
and allows peptidoglycan polymerization to
proceed uninhibited. Alternatively, S. aureus
with reduced or intermediate susceptibility to
vancomycin, such as heterovariant
vancomycin-intermediate S. aureus (hVISA)
and vancomycin-intermediate S. aureus (VISA),
express the wild-type D-alanyl-D-alanine peptide
termini, but produce significantly thicker cell
walls [7]. This effectively creates excessive
vancomycin-peptidoglycan binding sites
within the cell wall and decreases the amount
of vancomycin that ultimately binds Lipid II
near the division septum, lessening the
antimicrobial impact of the agent.
Oritavancin, while structurally related to
vancomycin, possesses unique mechanisms of
action secondary to the inclusion of the highly
hydrophobic N-alkyl-p-chlorophenylbenzyl
Fig. 1 Structures of vancomycin (left) and oritavancin (right)
Fig. 2 Components of lipid II
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group and two 4-epi-vancosamine residues
(Fig. 3). Though it has been shown that
oritavancin is capable of binding to the
D-alanyl-D-alanine peptidoglycan termini of
Lipid II by means similar to vancomycin, a
second distinct peptidoglycan-binding pocket
has also been identified [5, 8–10]. This binding
pocket, between the hydrophobic tail group
and the nearby 4-epi-vancosamine, is believed
to interact with peptides near, but distinct from
the terminal D-alanyl-D-alanine (or D-lactate) in
both S. aureus and enterococci [8, 11]. Thus,
oritavancin is capable of maintaining binding
affinity for the modified peptidoglycan peptide
termini of vancomycin-resistant organisms.
Additionally, oritavancin has been observed
to inhibit transpeptidation, the other essential
enzymatic step in peptidoglycan
polymerization. When oritavancin binds to
newly formed template peptidoglycan chains
near the cell membrane in a fashion
independent of Lipid II, the activity of the
bacterial transpeptidase is obstructed by steric
hindrance associated with the hydrophobic tail
group of oritavancin [11]. Inhibition of
transpeptidase prevents the cross-linking of
neighboring peptidoglycan chains and reduces
cell wall integrity. Though both binding of
oritavancin to Lipid II and mature
peptidoglycan has been observed, it appears
that oritavancin, contrary to vancomycin,
displays greater inhibition of transpeptidation
than transglycosylation [5, 11].
In another departure from the earlier
glycopeptides, lipoglycopeptides including
oritavancin have been proposed to possess
bacterial membrane binding capabilities.
While some investigators have observed
bacterial membrane insertion to occur only in
the absence of cell wall associated
peptidoglycan-binding sites, more recent
research has identified oritavancin associated
membrane depolarization and permeabilization
among intact staphylococci and enterococci
[10, 12]. This membrane-targeted mechanism
of action is proposed to be independent of
Fig. 3 Oritavancin bacterial binding sites. a Oritavancin
binding to template peptidoglycan at cleft between
hydrophobic tail group and 4-epi-vancosamine.
b Oritavancin hydrophobic tail group insertion into
bacterial cell membrane. c Oritavancin binding to
D-alanyl-D-alanine stabilized by hydrophobic tail group
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cellular growth and division. This is supported
by the rapid bactericidal activity of oritavancin
against stationary phase and biofilm-associated
organisms, both often more resilient to
antimicrobial treatment [13].
Although the lipoglycopeptides, including
oritavancin, have been observed to dimerize
through interactions between hydrophobic tail
groups, dimerized oritavancin has not been
observed bound to Lipid II, peptidoglycan, or
bacterial membranes. Thus, it is currently
unclear if this capability plays a role in the
increased antimicrobial potency of oritavancin.
MICROBIOLOGY
Oritavancin exhibits potent activity against
many resistant Gram-positive organisms
including methicillin-susceptible S. aureus
(MSSA), MRSA, VRSA, VISA, and both
vancomycin-susceptible enterococci (VSE) and
VRE [14–18]. Against MRSA, oritavancin has
been shown to be eightfold more potent than
daptomycin and 16- to 32-fold more potent
than vancomycin and linezolid when tested
against isolates in both the US and Europe [16].
Regardless of geographic region, it
demonstrated equal activity, inhibiting 75.9%
and 73.7% of MRSA isolates at a concentration
of 0.03 mg/L from the US and Europe,
respectively. Additionally, against multi-drug
resistant (MDR) strains, oritavancin had
minimum inhibitory concentrations (MICs)
that were 8- to 32-fold lower than those of
active comparators with a MIC for 50% of
isolates (MIC50) of 0.03 mg/L and a MIC for
90% of isolates (MIC90) of 0.06 mg/L, compared
to vancomycin with a MIC50 and MIC90 of
1 mg/L, daptomycin with a MIC50 of 0.25 mg/L
and MIC90 of 0.5 mg/L, and linezolid with a
MIC50 of 1 mg/L and MIC90 of 2 mg/L. It is
important to note that these MIC data were
collected using 0.002% polysorbate-80 as
recommended by the Clinical and Laboratory
Standards Institute (CLSI) guidelines, which
results in lower MIC data than historically
seen with this agent. Oritavancin also
demonstrates potent activity against
methicillin-resistant coagulase-negative
Staphylococci (MRCoNS) as well as several
strains of Streptococci, with a MIC50 and
MIC90 of 0.06 and 0.12 mg/L for MRCoNS,
0.06 and 0.25 mg/L for S. pyogenes, and 0.03
and 0.06 mg/L for S. agalactiae [18]. MIC50,
MIC90, and MIC ranges of oritavancin against
staphylococci, streptococci, and enterococci
causing SSTIs from the US in 2010–2013 are
shown in Table 1. Of note, the CLSI
susceptibility breakpoint for oritavancin
against staphylococci, streptococci, and VSE
are B0.12, B0.25, and B0.12 mg/L,
respectively, and the European Committee on
Antimicrobial Susceptibility Testing (EUCAST)
break points are B0.125, B0.25 mg/L for
S. aureus and streptococci, respectively [19]. In
addition to MRSA, oritavancin has in vitro
activity against hVISA, VISA, and VRSA with
reported MIC ranges of 0.03–2, 0.12–4, and
0.12–2 mg/L, respectively [20–22]. The reported
MIC90 for oritavancin against these organisms is
1, 2, and 0.5 compared to a MIC90 for
vancomycin of 2, 8, and[512 mg/L for hVISA,
VISA, and VRSA, respectively [20]. Additionally,
oritavancin has been shown to have activity
against daptomycin non-susceptible strains of
S. aureus with a MIC range of 0.03–0.12 mg/L
[21]. Although oritavancin clearly has some
activity against these organisms in vitro, the
MIC ranges do cross above the susceptibility
breakpoint so caution should be used if
considering use of this agent for these
organisms clinically.
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A unique characteristic about oritavancin,
compared to other lipoglycopeptides, is that it
has potent in vitro activity against both VSE and
VRE [17, 18]. When tested against enterococci
from bacteremic patients, the MIC50 and MIC90
for oritavancin against vancomycin-susceptible
E. faecalis were 0.015 and 0.03 mg/L and E.
faecium of B0.008 and B0.008 mg/L, both of
which were lower than the MICs for ampicillin,
vancomycin, daptomycin, and linezolid.
Oritavancin also exhibited two- to eightfold
greater activity than ampicillin, daptomycin,
and linezolid against VanA-mediated
vancomycin-resistant E. faecalis with an
oritavancin MIC50 of 0.25 mg/L and MIC90 of
0.5 mg/L, and was 8- to 64-fold more potent
against VanA-mediated vancomycin-resistant E.
faecium than quinupristin-dalfopristin,
linezolid, and daptomycin with an oritavancin
MIC50 of 0.03 mg/L and MIC90 of 0.12 mg/L.
However, it is important to note that the MIC
range for these organisms did range from 0.03
to 1 mg/L and B0.008 to 0.5 mg/L for E. faecalis
and E. faecium, respectively [17, 18].
Additionally, against enterococci from skin
and soft tissue infections from the US and
Europe, VanA-mediated vancomycin-resistant
E. faecalis had an oritavancin MIC50 of
0.25 mg/L and MIC90 of 0.5 mg/L [15]. These
values were 16-times higher than for
vancomycin-susceptible isolates, for which the
observed MIC50 and MIC90 were 0.015 and
0.03 mg/L, respectively. All
vancomycin-susceptible and VanB-mediated
vancomycin-resistant strains had equivalent
oritavancin MIC50 of 0.004 mg/L and MIC90 of
0.008 mg/L, while higher MIC50 and MIC90 of
0.03 and 0.12 mg/L were obtained for VanA
strains. Additionally, oritavancin has been
shown to have synergistic activity against VRE
when given with beta-lactams, reducing the
vancomycin-resistant E. faecium MIC range
from 0.03–0.12 mg/L when given alone to
\0.01–0.12 mg/L when given with ceftaroline,
ceftriaxone, or ampicillin [21].
In addition to the above mentioned
Gram-positive organisms, oritavancin has
demonstrated activity against Clostridium
difficile [23]. When studied against 33
genotypically distinct C. difficile isolates,
oritavancin MICs by broth microdilution
ranged from 0.06 to 1 mg/L with a MIC90 of
1 mg/L. Additionally, it had an MIC90 two- to
fivefold lower than metronidazole and
vancomycin and was considered to be at least
fourfold more potent than vancomycin against
Table 1 MIC50, MIC90, and MIC ranges of oritavancin against staphylococci, streptococci, and enterococci causing skin
and skin structure infections from the US in 2010–2013 [15]
Organisms MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L)
MSSA B0.008–0.25 0.03 0.06
MRSA B0.008–0.25 0.03 0.06
S. pyogenes B0.008–0.5 0.03 0.12
S. agalactiae B0.008–0.25 0.03 0.12
VSE (E. faecium) B0.008 B0.008 B0.008
VRE (E. faecium) B0.008–0.12 0.015 0.06
MIC minimum inhibitory concentration, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-susceptible
Staphylococcus aureus, VRE vancomycin-resistant enterococci, VSE vancomycin-susceptible enterococci
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76% of the C. difficile isolates. There have been
few studies looking at oritavancin activity
against C. difficile which have shown that
oritavancin may adhere to spores, affecting
spore recovery, and retaining antimicrobial
activity even after washing [24]. These results
are very promising for oritavancin’s potential
role in C. difficile infection in the future.
However, additional studies will need to be
done before it can be recommended for this
indication.
PHARMACOKINETICS
Oritavancin possesses both similarities and
distinctions compared to the pharmacokinetic
profile of vancomycin. When intravenously
administered across a range of doses both as
individual and multiple infusions, oritavancin
displays consistent linear kinetics [25]. A peak
serum concentration of 140 mg/L is obtained
following a single 1200 mg dose infused over
3 h [26]. The observed volume of distribution
approximates 1 L/kg and 85–90% of the
oritavancin is bound to serum proteins [27].
Owing again to the addition of the highly
hydrophobic N-alkyl-p-chlorophenylbenzyl tail
group, oritavancin possesses a prolonged
half-life. Following an initial distribution
phase, the terminal half-life ranges from
200–300 h. Less than 10% of the observed
peak concentration remains in serum 24 h
post-infusion. Distribution of oritavancin to
blister fluid is limited to approximately 20% of
simultaneous serum concentrations, but
remains several folds above the MIC90 of
organisms such as S. aureus and enterococci
[28]. Oritavancin is predominantly cleared via
the reticuloendothelial system, accumulating
most notably in macrophages of the liver
(Kupffer cells), kidney, spleen and lungs, as
well as in the intestinal mucosa, thymus, and
lymph nodes. Release and subsequent
elimination of oritavancin from these tissues
has been observed to be slow, and following a
single dose of oritavancin only trace amounts of
the administered dose are recovered from urine
(\5%) and feces (\1%) respectively by day seven
[25, 29]. Consequently, dose adjustment for
renal or hepatic insufficiency is not required.
No evidence of hepatically modified
metabolites has been found.
PHARMACODYNAMICS
Oritavancin has been observed to possess rapid
bactericidal activity against a broad array of
Gram-positive organisms including those with
reduced susceptibility to vancomycin. This
activity is concentration-dependent and best
predicted by the peak serum concentration to
MIC ratio (Cmax:MIC) and the area under the
curve to MIC ratio (AUC:MIC) [30–32]. While
pharmacodynamic target magnitudes certainly
vary by model and isolate tested, in a
neutropenic murine thigh infection model
utilizing five different isolates of S. aureus,
the average AUC:MIC at 24 h required for
bacterial stasis, 1-log10, and 2-log10
colony-forming unit (CFU) reductions was
approximately 90, 100, and 110, respectively
[32]. It has also been noted in a number of
pharmacodynamic experiments with dose
fractionation, that front-loaded regimens
with a single dose on day one produce
greater reductions in bacterial burden than
the same cumulative dose administered over
several days [30–32]. This observation in turn
supported the early investigation into single
1200 mg doses of oritavancin being used in
the treatment of skin and soft tissue infections
[33].
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In time-kill experiments utilizing static
concentrations approximating the unbound
oritavancin in serum following either a 200 or
800 mg dose, bactericidal activity against all
organisms tested (including MSSA, MRSA,
hVISA, VISA, VRSA, vancomycin-susceptible
Enterococcus faecalis, and VRE) was reported by
24 h [14]. Notably, against the three MRSA
isolates tested, bactericidal activity was
achieved in 1 h or less. None of the
comparator agents [vancomycin, teicoplanin,
linezolid and daptomycin (dosed at 4 mg/kg)]
were found to possess bactericidal activity
across all tested isolates, and no agent other
than oritavancin achieved bactericidal activity
against any of the VRE isolates tested. Similar
rapid bactericidal activity of oritavancin was
observed in subsequent experiments utilizing
drug concentrations simulating the free
oritavancin exposure with a single 1200 mg
and three clinical MRSA isolates [34].
Intriguingly, the potent bactericidal activity
of oritavancin is maintained against stationary
phase and biofilm-associated S. aureus, both of
which are often less susceptible to
antimicrobials [35]. When tested against a
substantial inoculum (about 107 CFU/mL) of
MSSA or MRSA in nutrient depleted media, a
static concentration of oritavancin
approximating unbound drug at the peak
serum concentration (fCmax) following a 200
or 800 mg dose (4 and 16 mg/L, respectively)
consistently produced bactericidal killing.
Additionally, the 16 mg/L dose of oritavancin
tested also produced bactericidal activity
against a VRSA isolate, while the 4 mg/L dose
produced a 2.2 log10 CFU/mL reduction. Of the
comparator agents [vancomycin, rifampin,
linezolid, and daptomycin (dosed at 4 mg/kg)],
daptomycin and rifampin both achieved
bactericidal activity against the MRSA isolate
tested at their respective fCmax. However, no
comparator agent achieved bactericidal activity
against the MSSA or VRSA isolates at 24 h.
ANIMAL STUDIES
Oritavancin has been studied in a variety of
animal models to determine its tissue and bone
penetration and therefore potential role against
Gram-positive organisms causing invasive
diseases including meningitis, endocarditis,
and osteomyelitis [30, 36–39]. When studied
against VSE and both VanA- and
VanB-mediated VRE endocarditis in rabbits,
oritavancin displayed heterogeneous
distribution throughout the cardiac
vegetations [39]. In those rabbits with aortic
endocarditis, twice-daily oritavancin was the
only glycopeptide antibiotic tested that
displayed significant activity regardless of the
phenotype of enterococcal strains. When
compared against vancomycin in rabbits with
MRSA left-sided endocarditis, once-daily
oritavancin was determined to be equally
effective in both clearing the bacteremia and
in reducing bacterial counts in the vegetations
and tissues [36]. In a rabbit model of meningitis
caused by Streptococcus pneumoniae, a single dose
of oritavancin was shown to reduce bacterial
titers in cerebrospinal fluid (CSF) almost as
rapidly as continuous infusion ceftriaxone
[37]. Maximum concentrations of oritavancin
in the CSF were reached several hours after
administration, and although the estimated CSF
penetration was relatively low at 1–5%, the
highly active in vivo activity resulted in reduced
bacterial titers, decreased inflammatory
markers, and sterilization of the CSF. However,
the tolerability of such high doses needed to
penetrate into the CSF is still to be determined
in humans. Oritavancin has also been studied in
rabbits to determine the differential distribution
from serum to bone tissue [40]. Following a
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5 min infusion, oritavancin serum
concentrations were greater than or equal to
10 mg/L for at least 24 h, which is several times
higher than the MIC90 for S. aureus (0.06 mg/L)
and S. pneumoniae (B0.008 mg/L). Additionally,
bone concentrations remained above the MIC90
for S. aureus for over 168 h following a single
20 mg/kg dose.
In addition to these above mentioned
organisms, oritavancin has been compared to
clindamycin and vancomycin on its ability to
induce C. difficile in hamsters [41]. Following
oritavancin exposure, there was no evidence of
C. difficile germination or toxin production in
both the hamsters and the in vitro gut models.
Additionally, oritavancin reduced C. difficile
total counts and demonstrated potential
activity against the spores, indicating a
possible treatment option for C. difficile
infections in the future.
Clinical Trials
Clinical trials presented here are related to the
registration of oritavancin with a novel
therapeutic dosing scheme and earlier trials
utilizing different dosing regimens were not
included. To evaluate the non-inferiority of
front-loaded oritavancin dosing regimens
compared to infrequent dosing in complicated
skin and skin structure infections (cSSSI), a
phase II, multicenter, randomized,
double-blind, parallel, active-comparator study
was completed.(33) The single or infrequent
doses for the treatment of complicated skin and
skin structure infections (SIMPLIFI;
ClinicalTrials.gov identifier, NCT00514527)
study included adult patients with a cSSSI
either suspected or proven to be caused by a
Gram-positive pathogen. To meet the definition
of cSSSI for the purposes of this study, patients
were required to have one or more of the
following: infection required surgical
intervention within 48 h of enrollment;
infection suspected or confirmed to involve
deep subcutaneous tissue (excluding fascia or
muscle layers); significant underlying disease
present to complicate treatment, including
diabetes, bacteremia, cellulitis with C3% of
total body surface area, corticosteroid therapy,
cirrhosis, burn, radiation therapy, or known
immune suppression. There were three
oritavancin treatment groups for comparison
including daily (200 mg daily for 3–7 days),
infrequent (800 mg on day 1 with an optional
400 mg on day 5), and single-dose (1200 mg as
one-time dose) groups. The primary objective of
the study was the clinical response in the
clinically evaluable (CE) and intention-to-treat
(ITT) populations at test of cure (TOC) on days
21–29, decided by the investigator, as cure,
improvement, failure, or indeterminate based
on clinical signs and symptoms.
A total of 302 patients were included in the
ITT population (100 in the daily group, 103 in
the infrequent group, and 99 in the single-dose
group), of which 228 were included in the CE
population [33]. Demographics and baseline
characteristics were similar among all
treatment groups, with 37.7% of patients
having major abscesses, 31.8% wound
infections, and 30.5% cellulitis. The most
commonly isolated pathogen was S. aureus
(87.6%), 49% being MRSA, with other
Gram-positive organisms isolated including
Streptococcus pyogenes (5.7%), Streptococcus
agalactiae (3.8%), and E. faecalis (3.8%). The
oritavancin MIC90 for all S. aureus isolated was
0.12 mg/L, and the overall range of MICs for
S. aureus was 0.008–0.5 mg/L. There was no
difference in the primary outcome of clinical
cure/improvement in the ITT population,
occurring in 72.4%, 78.2%, and 81.8% in the
daily, infrequent, and single-dose groups,
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respectively [90% confidence interval (CI), -1.7
to 17.8 for comparison of 1200 and 200 mg
groups; 90% CI, -5.8 to 14.6 for comparison of
800 and 200 mg groups]. Similarly, when
evaluating the results for only those with
S. aureus isolated (both MRSA and MSSA), cure
rates were similar among groups with 67.4% for
the daily group, 79.5% for the infrequent group,
and 78.9% for the single-dose group. Over half
of the patients in the study experienced an
adverse event (56%, 61.2%, and 55.6% in the
daily, infrequent, and single-dose groups,
respectively), of which the majority were
considered to be mild or moderate in severity
(85.7%) and unrelated to study medication
(58.0%). Based on these phase II study results,
oritavancin is considered safe, effective, and
well tolerated as a 1200 mg single dose for the
treatment of cSSSI caused by Gram-positive
organisms, including MRSA.
Two pivotal double-blind, randomized phase
III studies, SOLO I and II (ClinicalTrials.gov
identifiers, NCT01252719 and NCT01252732,
respectively), were completed to assess the
clinical efficacy and safety of the previously
studied 1200 mg single dose of oritavancin in
acute bacterial skin and skin structure infections
(ABSSSIs) [42, 43]. These studies included
patients 18 years or older with ABSSSIs
thought or proven to be caused by a
Gram-positive organism with a lesion
surrounded by erythema, edema, or an
induration of at least 75 cm2. Patients were
either given oritavancin 1200 mg as a single
dose, or vancomycin 1000 mg or 15 mg/kg
dosed twice daily for 7–10 days. The primary
outcome was a composite endpoint of the
following three criteria: cessation of spreading
or reduction in lesion size, absence of fever, and
no need for a rescue antibiotic at 48–72 h.
Non-inferiority of oritavancin against
vancomycin was defined by a 10%
non-inferiority margin at the 1-sided a level of
0.025, with a primary efficacy outcome rate
assumed to be 75%. Key secondary outcomes
were investigator-assessed clinical cure at the
post-therapy evaluation (PTE) and a reduction
in lesion size of 20% or more at the early clinical
evaluation (ECE). There were no significant
differences in demographics or baseline
characteristics between groups or between
studies. The majority of patients in SOLO I
had cellulitis (51.2% and 48.6% for oritavancin
and vancomycin, respectively) and abscesses
(29.5% and 29.4%, respectively) while the
patients in SOLO II were more evenly split
among wound (38.0% and 35.1%, respectively),
cellulitis (28.6% and 33.3%, respectively), and
abscesses (33.4% and 31.7%). The median
lesion area at baseline was 248.0 versus
225.6 cm2, and 287.8 versus 308.8 cm2 in the
oritavancin versus vancomycin in SOLO I and
SOLO II, respectively. A positive culture
occurred in 61.1% and 60.5% in the
oritavancin and vancomycin groups in SOLO
I, and 69.8% and 70.1% in the oritavancin and
vancomycin groups in SOLO II. The most
common pathogen isolated from the infection
site in both studies was S. aureus and MRSA,
isolated in 201 and 204 patients in SOLO I and
SOLO II, respectively. Of note, there were few
patients included in these studies with positive
blood cultures as baseline. For SOLO I, there
were 18 and 9 patients compared to SOLO II
with 6 and 10 patients with positive blood
cultures in the oritavancin and vancomycin
groups, respectively.
Oritavancin met the predetermined
non-inferiority criteria against vancomycin in
the modified ITT (mITT) population with 82.3%
of patients in the oritavancin group versus
78.9% in the vancomycin group (absolute
difference 3.4, 95% CI, -1.6 to 8.4) and 80.1%
in the oritavancin group versus 82.9% in the
10 Infect Dis Ther (2016) 5:1–15
vancomycin group (absolute difference -2.7,
95% CI, -7.5 to 2.0) meeting the primary
composite endpoint in SOLO I and SOLO II,
respectively. Additionally, when evaluating the
clinical cure at PTE [79.6% vs. 80.0%; absolute
difference -0.4 (95% CI, -5.5 to 4.7) and 82.7%
vs. 80.5%; absolute difference 2.2 (95% CI, -2.6
to 7.0) for oritavancin vs. vancomycin in SOLO
I and SOLO II, respectively] and reduction in
lesion size of 20% or more at ECE [86.9% vs.
82.9%; absolute difference 4.1 (95% CI, -0.5 to
8.6) and 85.9% vs. 85.3%; absolute difference
0.6 (95% CI, -3.7 to 5.0) for oritavancin vs.
vancomycin in SOLO I and SOLO II,
respectively], oritavancin also met the
predetermined non-inferiority margin of less
than a 10% difference. In those patients with
isolated MRSA in the microbiological ITT
(MicroITT) population, the primary efficacy
endpoint occurred in 80.8% of those on
oritavancin versus 80.0% of those on
vancomycin [absolute difference 0.8 (95% CI,
-10.1 to 11.7)] in SOLO I, and 82.0% of those
on oritavancin versus 81.2% of those on
vancomycin [absolute difference 0.8 (95% CI,
-9.9 to 11.5)] in SOLO II, again showing similar
efficacy between groups in both studies.
Treatment-emergent adverse events (TEAEs)
occurred similarly between groups with 63.8%
versus 60.0% and 50.9% versus 50.2% of
patients reporting at least one adverse event in
the oritavancin versus vancomycin groups in
SOLO I and SOLO II, respectively. However,
these TEAEs were generally considered to be
mild in severity and only 5.8% in the
oritavancin group versus 3.8% in the
vancomycin group in SOLO I and 3.6% in the
oritavancin group versus 2.6% in the
vancomycin group in SOLO II reported
discontinuation of study drug due to adverse
events. Additionally, in SOLO II, 5 cases of
osteomyelitis were reported as an adverse event
in the oritavancin group compared to 0 cases in
the vancomycin group, and in SOLO I, one case
of osteomyelitis was reported in each group. It
was noted that the 5 events in SOLO II occurred
within the first 9 days of initiating the study
medication and the authors suggest that the
osteomyelitis was likely present at the time of
enrollment, but missed by the investigators.
Based on this data, osteomyelitis is listed as a
warning for oritavancin, and it is recommended
to monitor patients for signs and symptoms of
osteomyelitis and to initiate appropriate
alternative therapy if it is suspected [19]. Of
note, due to the extended half-life of
oritavancin, safety effects were evaluated at
the 60 day follow-up assessment and the
investigators failed to identify any prolonged
or delayed adverse events in the oritavancin
group [42, 43]. Therefore, based on the SOLO I
and SOLO II studies, oritavancin is considered a
safe and effective single-dose alternative to
traditional therapies for ABSSSIs caused by
Gram-positive organisms.
In addition to the completed ABSSSI studies,
a new trial on the ClinicalTrials.gov registry and
results database is currently recruiting for a
pediatric study looking to evaluate oritavancin
for suspected or confirmed bacterial infections
in children (ClinicalTrials.gov identifier,
NCT0213430). Furthermore, a safety,
tolerability and pharmacokinetics study of a
new oritavancin formulation with an adjusted
infusion time, concentration, and
reconstitution/administration solution is also
recruiting at this time (ClinicalTrials.gov
identifier, NCT02471690).
SAFETY AND DRUG INTERACTIONS
Overall, the most commonly reported adverse
events in SOLO I and SOLO II, reported inC3%of
patients, were headache, nausea, vomiting, limb
Infect Dis Ther (2016) 5:1–15 11
and subcutaneous abscess, and diarrhea [19, 43,
44]. Adverse events leading to discontinuation of
therapy only occurred in 3.7% of those patients
on oritavancin, with the most common reasons
being cellulitis (0.4%) and osteomyelitis (0.3%).
Serious adverse events were only reported in
5.8% and 5.9% of patients on oritavancin and
vancomycin, respectively. Additionally,
laboratory abnormalities were also relatively
low with only two laboratory parameters,
alanine aminotransferase and aspartate
aminotransferase level elevations, occurring in
C1.5% of patients taking oritavancin.
One distinct different between oritavancin
and other glycopeptides is its potential for
drug–drug and drug-lab interactions.
Oritavancin was studied in healthy volunteers
and found to be a nonspecific, weak inhibitor of
cytochrome P450 (CYP) 2C9 and CYP2C19 and
an inducer of CYP3A4 and CYP2D6 [19, 45].
When oritavancin was given with warfarin and
omeprazole (CYP2C9 and CYP2C19 substrates,
respectively), there was a 31% increase in the
mean AUC of warfarin and a 15% increase in the
ratio of omeprazole to 5-hydroxy-omeprazole.
Additionally, oritavancin interactions with the
CYP3A4 and CYP2D6 enzymes resulted in an
18% decrease in the mean AUC of midazolam
and a 31% decrease in the ratio of
dextromethorphan to dextrorphan
concentrations. Oritavancin also interacts with
several laboratory values due to its ability to bind
to the phospholipid reagent, preventing the
activation of coagulation in commonly used
laboratory coagulation tests [19]. The
laboratory tests affected include prolonged
activated partial thromboplastin time,
prolonged prothrombin time/international
normalized ratio, and, theoretically, prolonged
activated clotting time. These drug-laboratory
interactionsmake the use of these labs unreliable
and caution must be used when attempting to
monitor the anticoagulation effects of heparin
and warfarin during this time period. Due to this
interaction and the potential concern of these
unreliable monitoring tools, heparin is
contraindicated during the first 48 h after
oritavancin administration [19]. Additional
studies are listed on the ClinicalTrials.gov
registry and results database that will further
evaluate the interaction with warfarin and help
clinicians better understand how to handle
patients who need anticoagulation while on
oritavancin therapy.
CONCLUSIONS
Oritavancin is a semisynthetic lipoglycopeptide
antibiotic that was recently approved for the
treatment of ABSSSI in a time when there is a
rise in the emergence of resistance and a deficit
in the development of new antibiotics to treat
these MDR organisms. It is unique in that its
additional mechanisms of action allow it to
have enhanced antimicrobial potency against
both VanA- and VanB-mediated VRE, unlike the
earlier glycopeptides. Oritavancin possesses a
prolonged half-life ranging from 200–300 h,
allowing for the convenience of single doses to
complete a 7-day treatment duration. Although
oritavancin is only currently FDA approved for
ABSSSI, this agent may eventually have a role in
additional indications where new innovative
therapy is needed including bacteremia,
infective endocarditis, and osteomyelitis;
however, additional studies would need to be
completed before they can be recommended in
these indications.
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